PT- 141

PT-141 (bremelanotide) is a synthetic peptide derived from Melanotan II . It is a 7-amino-acid cyclic heptapeptide with the molecular formula C50H68N14O10 . The compound functions as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R . PT-141 received FDA approval in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women . This approval makes PT-141 unique among research peptides.

2. Mechanism of Action

PT-141 acts primarily as an agonist at MC3R and MC4 receptors in the central nervous system . The peptide initiates its action in the hypothalamus and leads to downstream effects on sexual desire and arousal . MC4R receptors are present in many areas of the central nervous system and are involved in food intake and energy homeostasis . Interestingly, the precise mechanism by which receptor agonism improves sexual desire remains unknown, though one theory suggests PT-141 stimulates dopamine in the medial preoptic area, a region involved in sexual behavior .

[Image Placeholder: Chart showing PT-141 binding to MC4R receptors in the brain]
Alt text: PT-141 binding to MC4 receptors in the hypothalamus and central nervous system

3. Research Applications

Researchers have studied PT-141 for sexual function applications. Early studies demonstrated significant erectogenic effects in men with erectile dysfunction, with a 2004 study showing erections suitable for penetration in men with mild-to-moderate ED . Additional studies showed PT-141 increased sexual desire in women with female sexual arousal disorder . Consequently, PT-141 continues to be studied off-label for erectile dysfunction in men, though its only FDA-approved indication remains HSDD in premenopausal women .

[Image Placeholder: Infographic of PT-141 research applications across men and women]
Alt text: PT-141 research applications for sexual function in male and female populations

4. Safety and Adverse Events

Documented side effects from clinical trials include nausea (24-36%), flushing, headache, yawning, and spontaneous erections . Nausea has been a dose-limiting factor above certain thresholds . Additionally, studies have reported temporary changes in blood pressure and hypertension exacerbation . Importantly, hyperpigmentation and skin discoloration occurred in 1.9% of subjects in Phase 3 trials, with higher incidence in Black subjects (8.5%) .

5. Regulatory Status

PT-141 is an FDA-approved peptide for HSDD in premenopausal women . Researchers should note that no FDA-approved indication for PT-141 exists for men . Furthermore, PT-141 is only available by prescription as Vyleesi and is not approved for research use outside clinical settings . For more on peptide safety, review our Peptide Safety Guide. Externally, refer to the FDA guidelines on approved drugs and the PubMed research repository for peer-reviewed literature.

6. Conclusion

PT-141 (bremelanotide) is a unique peptide with FDA approval. Researchers study its central mechanism of action in sexual function. Nevertheless, off-label use requires caution due to documented safety considerations.